A carregar...
Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis
Selective depletion of CD20(+) B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal a...
Na minha lista:
| Publicado no: | Neurotherapeutics |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5722762/ https://ncbi.nlm.nih.gov/pubmed/28695471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-017-0557-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|